Correction

VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway (Oncogene, (2018), 37, 41, (5585-5586), 10.1038/s41388-018-0495-6)


Published in:
Oncogene

DOI:
10.1038/s41388-019-1096-8

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:
- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquires to puresupport@bib.sdu.dk
Correction: VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway

D. Elias1 · H. Vever1 · A.-V. Lænkholm2 · M. F. Gjerstorff1 · C. W. Yde3 · A. E. Lykkesfeldt3 · H. J. Ditzel1,4

© The Author(s) 2019. This article is published with open access

Correction to: Oncogene

https://doi.org/10.1038/s41388-018-0495-6

Since the publication of this Erratum, the Authors noticed a further error in Fig. 1c. The same image was inserted twice next to each other (second row: PRKCA, image for RamR7 and TamR8) instead of the correct image for TamR8. The corrected Fig. 1c has been provided below.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

* D. Elias
delias@health.sdu.dk
* H. J. Ditzel
hditzel@health.sdu.dk

1 Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
2 Department of Pathology, Slagelse Hospital, Slagelse, Denmark
3 Breast Cancer Group, Cell Death and Metabolism, Danish Cancer Society Research Center, Copenhagen, Denmark
4 Department of Oncology, Odense University Hospital, Odense, Denmark

Published online: 11 November 2019
Fig. 1

<table>
<thead>
<tr>
<th></th>
<th>MCF7/0.5</th>
<th>TamR1</th>
<th>TamR7</th>
<th>TamR8</th>
<th>TamR4</th>
</tr>
</thead>
<tbody>
<tr>
<td>FYN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRKCA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITPR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DPYD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRLR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GBP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>